Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06282999 · 2 trials · 1 indication
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) Midazolam
AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8). Midazolam
| Arm | Type | Description |
|---|---|---|
| Part A Cohort 1 | EXPERIMENTAL | - |
| Part A Cohort 2 | EXPERIMENTAL | - |
| Part A Cohort 3 | EXPERIMENTAL | - |
| Part A Cohort 4 | EXPERIMENTAL | - |
| Part A Cohort 5 | EXPERIMENTAL | - |
| Part B Cohort 1 | EXPERIMENTAL | - |
| Part B Cohort 2 | EXPERIMENTAL | - |
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Cohort 4 | EXPERIMENTAL | - |
| Cohort 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-06282999 | DRUG | Tablet, 10 mg, every 8 hours, 14 days |
| Placebo | DRUG | Tablet, 0 mg, every 8 hours, 14 days |
| midazolam | DRUG | Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14 |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG ...
PF-06282999 is an investigational small molecule being studied in healthy adult subjects. It is being evaluated for safety, tolerability, and pharmacokinetics, and for its effects on the approved drug midazolam. It is not approved for any disease and remains in clinical development.
PF-06282999 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The company is conducting Phase 1 clinical trials to assess the drug's safety and effects in healthy volunteers.
PF-06282999 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Two Phase 1 trials have been completed, both involving healthy adult subjects.
PF-06282999 has been studied in two completed Phase 1 trials: NCT01626976, which assessed safety, tolerability, and pharmacokinetics in 42 healthy adults, and NCT01707082, which tested safety and effects in 69 healthy overweight adults and effects on midazolam. Both trials were conducted in Belgium.
No alternative names for PF-06282999 have been disclosed. The drug is identified solely by its code name PF-06282999 in clinical trial records. It is a small molecule being developed by Pfizer.